Connecting You to Tomorrow's Biotechnology Innovations
H1, a New York-based healthcare data-driven solutions provider, today announced continued growth and expansion of its global healthcare analytics platforms marked by strong top-line revenue growth. In the past year, H1 has grown from an initial team of five employees to over 150 employees globally, with international offices in New York, London, Seattle, and Hyderabad, India. With a team of over […]
A new study from Indiana University suggests that a drug proven safe for use in people may prevent opioid tolerance and physical dependence when used in combination with opioid-based pain medications. Researchers in the Linda and Jack Gill Center for Biomolecular Science at IU Bloomington have discovered that a compound previously tested to treat osteoarthritis pain appears […]
Indiana University researchers have made an important step forward in the design of drugs that fight the hepatitis B virus, which can cause liver failure and liver cancer. It’s estimated that 2 billion people worldwide have had a hepatitis B virus infection in their lifetime, with about 250 million — including 2 million Americans — […]
A recently-published study shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States. Cheng Kao, a professor in the IU Bloomington College of Arts and Sciences‘ Department of Molecular and Cellular […]
UNM Cancer Center Scientist co-leads international drug targets effort to create open-source archive for drug discovery, development, and safety Most aspirin users don’t know what aspirin does to make you feel better. Most doctors and scientists didn’t know, either, until recently. In fact, scientists know how only a handful of drugs really work and they […]
The Alzheimer’s Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna® for use as a cancer therapy) in patients with Alzheimer’s disease. Nilotinib is an FDA-approved drug for the treatment […]
As of 2016, we still don’t have a single approved drug to cure or even slow the progression of diseases caused by damage to the brain’s neurons. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) are determined to change that. Today, they announce a $10 million investment to develop effective […]